Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data

Mohamed Attauabi; Jens Frederik Dahlerup; Anja Poulsen; Malte Rosager Hansen; Marianne Kajbæk Verner-Andersen; Sule Eraslan; August Pilegaard Prahm; Natalia Pedersen; Lone Larsen; Tine Jess; Anders Neumann; Kent V Haderslev; Akbar Molazahi; Anders Berg Lødrup; Henning Glerup; Asser Mathiassen Oppfeldt; Michael Dam Jensen; Klaus Theede; Marianne Kiszka-Kanowitz; Jakob Benedict Seidelin; Johan Burisch

doi:10.1093/ecco-jcc/jjab192

Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data

Mohamed Attauabi, Jens Frederik Dahlerup, Anja Poulsen, Malte Rosager Hansen, Marianne Kajbæk Verner-Andersen, Sule Eraslan, August Pilegaard Prahm, Natalia Pedersen, Lone Larsen, Tine Jess, Anders Neumann, Kent V Haderslev, Akbar Molazahi, Anders Berg Lødrup, Henning Glerup, Asser Mathiassen Oppfeldt, Michael Dam Jensen, Klaus Theede, Marianne Kiszka-Kanowitz, Jakob Benedict SeidelinJohan Burisch

Research output: Contribution to journal › Journal article › Research › peer-review

15 Citations (Scopus)

Abstract

BACKGROUND AND AIMS: The health consequences of the coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn's disease (CD) remain largely unknown. We aimed to investigate outcomes and long-term effects of COVID-19 in patients with UC or CD.

METHODS: We conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28th, 2020 and April 1st, 2021, through medical records and questionnaires.

RESULTS: All 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 (N=230,087). A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N=46(14.4%), RR=2.49 (95%CI 1.91-3.26)) and CD (N=24(12.2%), RR=2.11 (95%CI 1.45-3.07)) as compared with the background population (N=13,306 (5.8%)). A similar pattern was observed for admission to intensive care (UC: N=8(2.51%), RR=27.88 (95%CI 13.88-56.00); CD: N=3 (1.52%), RR=16.92 (95%CI 5.46-52.46)). After a median of 5.1 months (IQR 4.5-7.9), 58 (42.3%) and 39 (45.9%) patients with UC and CD, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (OR=1.50 (95%CI 1.07-10.22), p=0.01) and severe COVID-19 (OR=2.76 (95%CI 1.05-3.90), p=0.04), but not with age nor presence of comorbidities.

CONCLUSION: In this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent affecting 43.7% of COVID-19 infected. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era.

Original language	English
Journal	Journal of Crohn's and Colitis
Volume	16
Issue number	5
Pages (from-to)	757–767
Number of pages	11
ISSN	1873-9946
DOIs	https://doi.org/10.1093/ecco-jcc/jjab192
Publication status	Published - 2022

Bibliographical note

Access to Document

10.1093/ecco-jcc/jjab192

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689957/pdf/jjab192.pdfLicence: Other

Cite this

Attauabi, M., Dahlerup, J. F., Poulsen, A., Hansen, M. R., Verner-Andersen, M. K., Eraslan, S., Prahm, A. P., Pedersen, N., Larsen, L., Jess, T., Neumann, A., Haderslev, K. V., Molazahi, A., Lødrup, A. B., Glerup, H., Oppfeldt, A. M., Jensen, M. D., Theede, K., Kiszka-Kanowitz, M., ... Burisch, J. (2022). Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data. Journal of Crohn's and Colitis, 16(5), 757–767. https://doi.org/10.1093/ecco-jcc/jjab192

Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data. / Attauabi, Mohamed; Dahlerup, Jens Frederik; Poulsen, Anja; Hansen, Malte Rosager; Verner-Andersen, Marianne Kajbæk; Eraslan, Sule; Prahm, August Pilegaard; Pedersen, Natalia; Larsen, Lone; Jess, Tine; Neumann, Anders; Haderslev, Kent V; Molazahi, Akbar; Lødrup, Anders Berg; Glerup, Henning; Oppfeldt, Asser Mathiassen; Jensen, Michael Dam; Theede, Klaus; Kiszka-Kanowitz, Marianne; Seidelin, Jakob Benedict; Burisch, Johan.

In: Journal of Crohn's and Colitis, Vol. 16, No. 5, 2022, p. 757–767.

Research output: Contribution to journal › Journal article › Research › peer-review

Attauabi, M, Dahlerup, JF, Poulsen, A, Hansen, MR, Verner-Andersen, MK, Eraslan, S, Prahm, AP, Pedersen, N, Larsen, L, Jess, T, Neumann, A, Haderslev, KV, Molazahi, A, Lødrup, AB, Glerup, H, Oppfeldt, AM, Jensen, MD, Theede, K, Kiszka-Kanowitz, M, Seidelin, JB & Burisch, J 2022, 'Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data', Journal of Crohn's and Colitis, vol. 16, no. 5, pp. 757–767. https://doi.org/10.1093/ecco-jcc/jjab192

Attauabi, Mohamed ; Dahlerup, Jens Frederik ; Poulsen, Anja ; Hansen, Malte Rosager ; Verner-Andersen, Marianne Kajbæk ; Eraslan, Sule ; Prahm, August Pilegaard ; Pedersen, Natalia ; Larsen, Lone ; Jess, Tine ; Neumann, Anders ; Haderslev, Kent V ; Molazahi, Akbar ; Lødrup, Anders Berg ; Glerup, Henning ; Oppfeldt, Asser Mathiassen ; Jensen, Michael Dam ; Theede, Klaus ; Kiszka-Kanowitz, Marianne ; Seidelin, Jakob Benedict ; Burisch, Johan. / Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data. In: Journal of Crohn's and Colitis. 2022 ; Vol. 16, No. 5. pp. 757–767.

@article{43036fbe73fe4d5c98a00a126b2091ac,

title = "Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data",

abstract = "BACKGROUND AND AIMS: The health consequences of the coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn's disease (CD) remain largely unknown. We aimed to investigate outcomes and long-term effects of COVID-19 in patients with UC or CD.METHODS: We conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28th, 2020 and April 1st, 2021, through medical records and questionnaires.RESULTS: All 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 (N=230,087). A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N=46(14.4%), RR=2.49 (95%CI 1.91-3.26)) and CD (N=24(12.2%), RR=2.11 (95%CI 1.45-3.07)) as compared with the background population (N=13,306 (5.8%)). A similar pattern was observed for admission to intensive care (UC: N=8(2.51%), RR=27.88 (95%CI 13.88-56.00); CD: N=3 (1.52%), RR=16.92 (95%CI 5.46-52.46)). After a median of 5.1 months (IQR 4.5-7.9), 58 (42.3%) and 39 (45.9%) patients with UC and CD, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (OR=1.50 (95%CI 1.07-10.22), p=0.01) and severe COVID-19 (OR=2.76 (95%CI 1.05-3.90), p=0.04), but not with age nor presence of comorbidities.CONCLUSION: In this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent affecting 43.7% of COVID-19 infected. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era.",

author = "Mohamed Attauabi and Dahlerup, {Jens Frederik} and Anja Poulsen and Hansen, {Malte Rosager} and Verner-Andersen, {Marianne Kajb{\ae}k} and Sule Eraslan and Prahm, {August Pilegaard} and Natalia Pedersen and Lone Larsen and Tine Jess and Anders Neumann and Haderslev, {Kent V} and Akbar Molazahi and L{\o}drup, {Anders Berg} and Henning Glerup and Oppfeldt, {Asser Mathiassen} and Jensen, {Michael Dam} and Klaus Theede and Marianne Kiszka-Kanowitz and Seidelin, {Jakob Benedict} and Johan Burisch",

note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn{\textquoteright}s and Colitis Organisation. All rights reserved. For permissions, please email: [email protected].",

year = "2022",

doi = "10.1093/ecco-jcc/jjab192",

language = "English",

volume = "16",

pages = "757–767",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data

AU - Attauabi, Mohamed

AU - Dahlerup, Jens Frederik

AU - Poulsen, Anja

AU - Hansen, Malte Rosager

AU - Verner-Andersen, Marianne Kajbæk

AU - Eraslan, Sule

AU - Prahm, August Pilegaard

AU - Pedersen, Natalia

AU - Larsen, Lone

AU - Jess, Tine

AU - Neumann, Anders

AU - Haderslev, Kent V

AU - Molazahi, Akbar

AU - Lødrup, Anders Berg

AU - Glerup, Henning

AU - Oppfeldt, Asser Mathiassen

AU - Jensen, Michael Dam

AU - Theede, Klaus

AU - Kiszka-Kanowitz, Marianne

AU - Seidelin, Jakob Benedict

AU - Burisch, Johan

PY - 2022

Y1 - 2022

N2 - BACKGROUND AND AIMS: The health consequences of the coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn's disease (CD) remain largely unknown. We aimed to investigate outcomes and long-term effects of COVID-19 in patients with UC or CD.METHODS: We conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28th, 2020 and April 1st, 2021, through medical records and questionnaires.RESULTS: All 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 (N=230,087). A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N=46(14.4%), RR=2.49 (95%CI 1.91-3.26)) and CD (N=24(12.2%), RR=2.11 (95%CI 1.45-3.07)) as compared with the background population (N=13,306 (5.8%)). A similar pattern was observed for admission to intensive care (UC: N=8(2.51%), RR=27.88 (95%CI 13.88-56.00); CD: N=3 (1.52%), RR=16.92 (95%CI 5.46-52.46)). After a median of 5.1 months (IQR 4.5-7.9), 58 (42.3%) and 39 (45.9%) patients with UC and CD, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (OR=1.50 (95%CI 1.07-10.22), p=0.01) and severe COVID-19 (OR=2.76 (95%CI 1.05-3.90), p=0.04), but not with age nor presence of comorbidities.CONCLUSION: In this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent affecting 43.7% of COVID-19 infected. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era.

AB - BACKGROUND AND AIMS: The health consequences of the coronavirus disease 2019 (COVID-19) among patients with ulcerative colitis (UC) and Crohn's disease (CD) remain largely unknown. We aimed to investigate outcomes and long-term effects of COVID-19 in patients with UC or CD.METHODS: We conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28th, 2020 and April 1st, 2021, through medical records and questionnaires.RESULTS: All 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 (N=230,087). A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N=46(14.4%), RR=2.49 (95%CI 1.91-3.26)) and CD (N=24(12.2%), RR=2.11 (95%CI 1.45-3.07)) as compared with the background population (N=13,306 (5.8%)). A similar pattern was observed for admission to intensive care (UC: N=8(2.51%), RR=27.88 (95%CI 13.88-56.00); CD: N=3 (1.52%), RR=16.92 (95%CI 5.46-52.46)). After a median of 5.1 months (IQR 4.5-7.9), 58 (42.3%) and 39 (45.9%) patients with UC and CD, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (OR=1.50 (95%CI 1.07-10.22), p=0.01) and severe COVID-19 (OR=2.76 (95%CI 1.05-3.90), p=0.04), but not with age nor presence of comorbidities.CONCLUSION: In this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent affecting 43.7% of COVID-19 infected. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era.

U2 - 10.1093/ecco-jcc/jjab192

DO - 10.1093/ecco-jcc/jjab192

M3 - Journal article

C2 - 34755858

VL - 16

SP - 757

EP - 767

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 5

ER -